Profile data is unavailable for this security.
About the company
Chongqing Genrix Biopharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of antibody drugs. The Company’s products mainly include monoclonal antibody drugs and bispecific antibody drugs under research. In terms of source innovation, the Company has established a new phage-based presented two technical platforms, the monoclonal antibody drug discovery technology platform and the bispecific antibody drug discovery technology platform and established an efficient recombinant antibody drug process development platform in the drug development process.
- Revenue in CNY (TTM)225.16m
- Net income in CNY-583.52m
- Incorporated2015
- Employees743.00
- LocationChongqing Genrix Biopharmaceutical Co LtdArea A, Block 2,No. 699, Maliu Avenue, Banan DistrictCHONGQING 401338ChinaCHN
- Phone+86 2 361758666
- Fax+86 2 361758011
- Websitehttp://www.genrixbio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Taiji Industry Group Co Ltd | 10.04bn | -352.52m | 9.90bn | 11.97k | -- | 2.80 | -- | 0.9859 | -0.8238 | -0.8238 | 18.98 | 6.42 | 0.7032 | 2.85 | 3.55 | 838,688.20 | -2.36 | 0.9924 | -6.94 | 3.04 | 26.30 | 43.37 | -3.35 | 1.08 | 0.4906 | 0.5756 | 0.5914 | 22.39 | -20.72 | 1.24 | -96.76 | -- | -3.36 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 709.13m | 64.21m | 9.90bn | 470.00 | 153.74 | 10.32 | -- | 13.96 | 0.1587 | 0.1587 | 1.75 | 2.36 | 0.3883 | 0.654 | 1.19 | 1,508,792.00 | 3.45 | 3.25 | 5.00 | 4.81 | 92.66 | 93.62 | 8.88 | 8.11 | 1.42 | 8.30 | 0.2906 | 7.39 | 18.69 | 26.88 | 18.24 | -- | 48.00 | -- |
| Youcare Pharmaceutical Group Co Ltd | 2.55bn | -233.99m | 10.24bn | 3.28k | -- | 2.99 | -- | 4.02 | -0.5306 | -0.5306 | 5.75 | 7.62 | 0.4537 | 2.18 | 4.03 | 777,123.10 | -4.30 | 5.90 | -5.97 | 8.92 | 47.55 | 63.64 | -9.48 | 7.49 | 1.49 | -41.24 | 0.1633 | 66.99 | -9.90 | -2.48 | -33.05 | -15.40 | 19.36 | -- |
| Chongqing Genrix Biophrmctcl Co Ltd | 225.16m | -583.52m | 10.63bn | 743.00 | -- | 5.94 | -- | 47.19 | -1.59 | -1.59 | 0.6141 | 4.88 | 0.0712 | 0.3088 | 10.33 | 303,044.90 | -18.45 | -- | -19.95 | -- | 90.99 | -- | -259.16 | -- | 7.37 | -- | 0.3694 | -- | 2,384.11 | -- | 0.5049 | -- | -- | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.47bn | 177.94m | 10.79bn | 1.81k | 59.81 | 1.15 | -- | 7.34 | 0.433 | 0.433 | 3.56 | 22.54 | 0.1482 | 0.6786 | 1.24 | 813,192.10 | 1.79 | 8.07 | 1.86 | 8.36 | 79.03 | 84.98 | 12.11 | 35.75 | 19.28 | -- | 0.0013 | 44.77 | -4.22 | -0.0082 | -26.42 | -13.26 | -4.72 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.90bn | 498.69m | 10.94bn | 2.03k | 21.71 | 3.52 | -- | 5.76 | 1.60 | 1.60 | 6.13 | 9.84 | 0.3413 | 0.9306 | 3.06 | 936,748.90 | 8.90 | 7.19 | 13.04 | 9.67 | 66.64 | 59.30 | 26.08 | 20.28 | 0.928 | 16.07 | 0.4604 | 35.89 | 57.21 | 34.33 | 148.19 | 52.76 | 31.58 | -- |
| Aurisco Pharmaceutical Co Ltd | 1.62bn | 424.54m | 10.98bn | 1.78k | 25.56 | 4.32 | -- | 6.76 | 1.06 | 1.06 | 4.07 | 6.26 | 0.4188 | 1.09 | 4.41 | 910,578.10 | 10.94 | 11.37 | 12.60 | 13.29 | 59.77 | 52.93 | 26.13 | 22.34 | 3.01 | 635.15 | 0.2806 | 31.53 | 16.89 | 20.47 | 22.59 | 13.77 | 49.45 | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 247.05m | 22.96m | 11.30bn | 65.00 | 483.12 | 7.74 | -- | 45.75 | 0.1132 | 0.1132 | 1.22 | 7.07 | 0.163 | 0.9556 | 2.26 | 3,800,801.00 | 1.51 | 5.44 | 1.58 | 5.64 | 81.39 | 92.99 | 9.30 | 36.90 | 7.84 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.58bn | 687.99m | 11.46bn | 8.26k | 16.96 | 1.62 | -- | 1.74 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
Data as of Feb 11 2026. Currency figures normalised to Chongqing Genrix Biopharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
32.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 12.30m | 13.81% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 5.38m | 6.05% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2025 | 2.51m | 2.82% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.75m | 1.96% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 1.48m | 1.67% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.45m | 1.63% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 1.24m | 1.40% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 956.59k | 1.07% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 947.84k | 1.07% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 707.87k | 0.80% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
